跳至主要内容
临床试验/NCT03455166
NCT03455166已完成不适用

Identification of New Prognostic Markers in Psoriatic Arthritis

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio0 个研究点目标入组 100 人开始时间: 2015年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
主要终点
Different markers concentration

研究概览

简要总结

Identification of possible markers associated with the onset and / or progression of psoriatic arthritis through comparison in patients with psoriasis alone (Ps) and patients with psoriasis with joint involvement (PsA), plasma levels of a panel of cytokines referable to the Th17 pathway , together with serum levels of MMPs, TIMPs and markers of bone remodeling.

The primary objective of this study is to verify whether the arthropathy component has an effect on the metabolic activity of osteoblasts. This will be determined through the study of the differences in serum concentrations, between Ps and PsA subjects, of "CTx", the parameter best characterized in terms of analytical variability and intra- and inter-individual variability, in the field of bone metabolism.

The secondary objective is the verification of the differences in serum concentrations of the series of parameters specified above, in order to define a complete pattern of variations that can identify the molecular pathways involved in the definition of psoriatic arthropathy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years
  • For Ps group:
  • plaque psoriasis no previous treatment with biological drugs
  • For PsA group: plaque psoriasis with arthropathy no previous treatment with biological drugs but in treatment as per clinical practice or, alternatively, last treatment with drug suspended by a number of days double compared to the half-life of the drug

排除标准

  • Age <18 years
  • Pregnancy
  • Neoplasia in progress or previous (<5 years)
  • Other acute or chronic inflammatory diseases
  • Other rheumatological diseases
  • Metabolic diseases of the primitive bone
  • Recent bone fractures (<6 months)
  • Anxiety, psychosis, depressive disorders
  • Inability to understand the information provided by the recruiter doctor
  • For Ps group:
  • treatment with biological drugs

研究组 & 干预措施

Psoriasis

Other

干预措施: Serum Markers (Diagnostic Test)

Psoriatic arthropathy

Other

干预措施: Serum Markers (Diagnostic Test)

结局指标

主要结局

Different markers concentration

时间窗: 1 year

Measurement in serum of: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13, TIMP-1, TIMP-2, TIMP-3, TIMP-4, OPG, RANKL, PINP, CTx-I, DKK1, SOST,IL-1beta, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, INFg, sCD40L, TNFalfa. Correlation with Ps or PsA, and with the severity of the disease

次要结局

未报告次要终点

研究者

发起方
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
申办方类型
Other
责任方
Sponsor

相似试验